Compounds > 2',6'-dimethoxychalcone
Page last updated: 2024-12-11

2',6'-dimethoxychalcone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5354779
CHEMBL ID33241
CHEBI ID191004
SCHEMBL ID977479

Synonyms (13)

Synonym
5452-98-2
nsc19032
nsc-19032
CHEMBL33241
CHEBI:191004
(e)-1-(2,6-dimethoxyphenyl)-3-phenylprop-2-en-1-one
2',6'-dimethoxychalcone
SCHEMBL977479
AKOS024287211
GMODFQAQVHNPNU-VAWYXSNFSA-N
2-propen-1-one, 1-(2,6-dimethoxyphenyl)-3-phenyl-
nsc 19032
2',6'-dimethoxychalcone, aldrichcpr
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic compoundA cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID669499Inhibition of ABCG2-mediated mitoxantrone efflux expressed in HEK293 cells at 2 uM after 48 hrs by flow cytometric analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
AID669500Inhibition of ABCG2-mediated mitoxantrone efflux expressed in HEK293 cells at 10 uM after 48 hrs by flow cytometric analysis2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.
AID606613Induction of Nrf2-mediated NQO1 gene expression in human BEAS2B cells at 10 uM after 16 hrs by RT-PCR analysis relative to untreated control2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells.
AID659236Increase in intracellular GSH level in human MCF7 cells expressing antioxidant response element at 10 uM after 24 hrs by HPLC analysis relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
A synthetic chalcone as a potent inducer of glutathione biosynthesis.
AID659235Increase in intracellular GSH level in human MCF7 cells expressing antioxidant response element at 10 uM after 6 hrs by HPLC analysis relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
A synthetic chalcone as a potent inducer of glutathione biosynthesis.
AID655021Antagonist activity at androgen receptor in human LNCAP cells assessed as decrease in prostate specific antigen mRNA level at 2.5 uM after 20 hrs by real time RT-PCR analysis relative to control2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Methoxychalcone inhibitors of androgen receptor translocation and function.
AID89021Inhibition of the production of Interleukin-1-beta from human peripheral blood monocytes stimulated with lipopolysaccharide (LPS)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
2'-substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis.
AID606521Induction of Nrf2-mediated GCLM gene expression in human BEAS2B cells at 10 uM after 16 hrs by RT-PCR analysis relative to untreated control2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells.
AID329735Cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bicalutamide
bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.		2.0710(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
sulforaphane
sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.		2.4720isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
vincristine
[no description available]		2.0410acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0610acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
2-tert-butylhydroquinone
2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent. 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group.		2.0710hydroquinonesfood antioxidant
elacridar
Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source		2.0710
chalcone
trans-chalcone : The trans-isomer of chalcone.		2.9540chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
2'-hydroxychalcone
2'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'.		1.9810chalcones;
phenols		anti-inflammatory agent
4'-methoxychalcone
4'-methoxychalcone: RN given refers to compound with no isomeric designation		2.7230chalcones
4'-hydroxychalcone
4'-hydroxychalcone: inhibits TNFalpha-induced NF-κB activation; structure in first source. 4'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4'.		1.9810chalcones;
phenols		anti-inflammatory agent;
antineoplastic agent
flavokawain b
flavokawain B: from Piper methysticum Forst (Kava Kava) roots; structure in first source. flavokawain B : A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities.		2.7530chalcones;
dimethoxybenzene;
phenols		anti-inflammatory agent;
antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
metabolite
2',5'-dihydroxychalcone
2',5'-dihydroxychalcone: structure given in first source		2.0710chalcones
2-chloro-4',6'-dimethoxy-2'-hydroxychalcone
2-chloro-4',6'-dimethoxy-2'-hydroxychalcone: induces glutathione biosynthesis; structure in first source		2.4620
4-dimethylamino-2',4',6'-trimethoxychalcone
[no description available]		1.9810aromatic compound
ConditionIndicatedRelationship StrengthStudiesTrials
Endotoxin Shock
[description not available]		01.9810
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		01.9810
Adverse Drug Event
[description not available]		02.0410
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		02.0410
Cancer of Prostate
[description not available]		02.0710
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0710